Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study

被引：5

作者：

Landgren, Ola ^{[1
]}

Weisel, Katja ^{[2
]}

Rosinol, Laura ^{[3
]}

Touzeau, Cyrille ^{[4
]}

Turgut, Mehmet ^{[5
]}

Hajek, Roman ^{[6
,7
]}

Mollee, Peter ^{[8
,9
]}

Kim, Jin Seok ^{[10
]}

Shu, Natalie ^{[11
]}

Hu, Xuguang ^{[12
]}

Li, Chuang ^{[12
]}

Usmani, Saad Z. ^{[13
]}

机构：

[1] Sylvester Comprehens Canc Ctr, Div Hematol, Miami, FL USA

[2] Univ Med Ctr Hamburg Eppendorf, Dept Oncol Hematol & BMT, Hamburg, Germany

[3] IDIBAPS, Hosp Clin, Barcelona, Spain

[4] Ctr Hosp Univ Nantes, Serv Hematol Clin, Nantes, France

[5] Ondokuz Mayis Univ, Div Hematol, Dept Internal Med, Fac Med, Samsun, Turkey

[6] Univ Hosp Ostrava, Dept Haematooncol, Ostrava, Czech Republic

[7] Univ Ostrava, Dept Haematooncol, Fac Med, Ostrava, Czech Republic

[8] Princess Alexandra Hosp, Dept Haematol, Brisbane, Qld, Australia

[9] Univ Queensland, Sch Med, Brisbane, Qld, Australia

[10] Yonsei Univ, Severance Hosp, Coll Med, Seoul, South Korea

[11] Parexel, Chengdu, Peoples R China

[12] Amgen Inc, Thousand Oaks, CA 91320 USA

[13] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2022年 / 198卷 / 06期

关键词：

relapsed or refractory multiple myeloma; proteasome inhibitor; carfilzomib; cytogenetics; CARFILZOMIB; DEXAMETHASONE;

D O I：

10.1111/bjh.18233

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

CANDOR compared the safety/efficacy of carfilzomib with dexamethasone and daratumumab (KdD) to carfilzomib with dexamethasone (Kd) in adults with relapsed/refractory multiple myeloma (RRMM). This CANDOR subgroup analysis evaluated outcomes based on cytogenetic risk. Overall response rates (KdD vs. Kd) were 81% versus 56% in high-risk and 87% versus 79% in standard-risk groups. Median progression-free survival was 11.2 versus 7.4 months in high-risk (hazard ratio, 0.56 [95% CI, 0.34, 0.93]) and not reached versus 16.6 months in standard-risk groups (0.56 [95% CI, 0.39, 0.80]). These data support the efficacy of KdD in RRMM treatment, including in patients with high-risk cytogenetics.

引用

页码：988 / 993

页数：6

共 15 条

[1] Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response [J].

Abdallah, Nadine ;

Rajkumar, S. Vincent ;

Greipp, Patricia ;

Kapoor, Prashant ;

Gertz, Morie A. ;

Dispenzieri, Angela ;

Baughn, Linda B. ;

Lacy, Martha Q. ;

Hayman, Suzanne R. ;

Buadi, Francis K. ;

Dingli, David ;

Go, Ronald S. ;

Hwa, Yi L. ;

Fonder, Amie ;

Hobbs, Miriam ;

Lin, Yi ;

Leung, Nelson ;

Kourelis, Taxiarchis ;

Warsame, Rahma ;

Siddiqui, Mustaqeem ;

Lust, John ;

Kyle, Robert A. ;

Bergsagel, Leif ;

Ketterling, Rhett ;

Kumar, Shaji K. .

BLOOD CANCER JOURNAL, 2020, 10 (08)

[2] Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma [J].

Avet-Loiseau, Herve ;

Fonseca, Rafael ;

Siegel, David ;

Dimopoulos, Meletios A. ;

Spicka, Ivan ;

Masszi, Tamas ;

Hajek, Roman ;

Rosinol, Laura ;

Goranova-Marinova, Vesselina ;

Mihaylov, Georgi ;

Maisnar, Vladimir ;

Mateos, Maria-Victoria ;

Wang, Michael ;

Niesvizky, Ruben ;

Oriol, Albert ;

Jakubowiak, Andrzej ;

Minarik, Jiri ;

Palumbo, Antonio ;

Bensinger, William ;

Kukreti, Vishal ;

Ben-Yehuda, Dina ;

Stewart, A. Keith ;

Obreja, Mihaela ;

Moreau, Philippe .

BLOOD, 2016, 128 (09) :1174-1180

[3] Relapsed refractory multiple myeloma: a comprehensive overview [J].

Bazarbachi, Abdul Hamid ;

Al Hamed, Rama ;

Malard, Florent ;

Harousseau, Jean-Luc ;

Mohty, Mohamad .

LEUKEMIA, 2019, 33 (10) :2343-2357

[4] Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR [J].

Chng, W-J ;

Goldschmidt, H. ;

Dimopoulos, M. A. ;

Moreau, P. ;

Joshua, D. ;

Palumbo, A. ;

Facon, T. ;

Ludwig, H. ;

Pour, L. ;

Niesvizky, R. ;

Oriol, A. ;

Rosinol, L. ;

Suvorov, A. ;

Gaidano, G. ;

Pika, T. ;

Weisel, K. ;

Goranova-Marinova, V. ;

Gillenwater, H. H. ;

Mohamed, N. ;

Feng, S. ;

Aggarwal, S. ;

Hajek, R. .

LEUKEMIA, 2017, 31 (06) :1368-1374

[5] Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

Dimopoulos, M. A. ;

Moreau, P. ;

Terpos, E. ;

Mateos, M., V ;

Zweegman, S. ;

Cook, G. ;

Delforge, M. ;

Hajek, R. ;

Schjesvold, F. ;

Cavo, M. ;

Goldschmidt, H. ;

Facon, T. ;

Einsele, H. ;

Boccadoro, M. ;

San-Miguel, J. ;

Sonneveld, P. ;

Mey, U. .

ANNALS OF ONCOLOGY, 2021, 32 (03) :309-322

[6]

Dimopoulos M, 2020, LANCET, V396, P186, DOI 10.1016/S0140-6736(20)30734-0

[7] Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial [J].

Facon, Thierry ;

Kumar, Shaji K. ;

Plesner, Torben ;

Orlowski, Robert Z. ;

Moreau, Philippe ;

Bahlis, Nizar ;

Basu, Supratik ;

Nahi, Hareth ;

Hulin, Cyrille ;

Quach, Hang ;

Goldschmidt, Hartmut ;

O'Dwyer, Michael ;

Perrot, Aurore ;

Venner, Christopher P. ;

Weisel, Katja ;

Mace, Joseph R. ;

Raje, Noopur ;

Tiab, Mourad ;

Macro, Margaret ;

Frenzel, Laurent ;

Leleu, Xavier ;

Ahmadi, Tahamtan ;

Wang, Jianping ;

Van Rampelbergh, Rian ;

Uhlar, Clarissa M. ;

Tromp, Brenda ;

Delioukina, Maria ;

Vermeulen, Jessica ;

Usmani, Saad Z. .

LANCET ONCOLOGY, 2021, 22 (11) :1582-1596

[8] Next Generation Sequencing-based Validation of the Revised International Staging System for Multiple Myeloma: An Analysis of the MMRF CoMMpass Study [J].

Goldsmith, Scott R. ;

Fiala, Mark A. ;

Dukeman, James ;

Ghobadi, Armin ;

Stockerl-Goldstein, Keith ;

Schroeder, Mark A. ;

Tomasson, Michael ;

Wildes, Tanya M. ;

Vij, Ravi .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (05) :285-289

[9] Carfilzomib for relapsed and refractory multiple myeloma [J].

Groen, K. ;

van de Donk, N. W. C. J. ;

Stege, C. A. M. ;

Zweegman, S. ;

Nijhof, I. S. .

CANCER MANAGEMENT AND RESEARCH, 2019, 11 :2663-2675

[10] Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX [J].

Kaufman, Jonathan L. ;

Dimopoulos, Meletios A. ;

White, Darrell ;

Benboubker, Lotfi ;

Cook, Gordon ;

Leiba, Merav ;

Morton, James ;

Joy Ho, P. ;

Kim, Kihyun ;

Takezako, Naoki ;

Moreau, Philippe ;

Sutherland, Heather J. ;

Magen, Hila ;

Iida, Shinsuke ;

Kim, Jin Seok ;

Miles Prince, H. ;

Cochrane, Tara ;

Oriol, Albert ;

Bahlis, Nizar J. ;

Chari, Ajai ;

O'Rourke, Lisa ;

Trivedi, Sonali ;

Casneuf, Tineke ;

Krevvata, Maria ;

Ukropec, Jon ;

Kobos, Rachel ;

Avet-Loiseau, Herve ;

Usmani, Saad Z. ;

San-Miguel, Jesus .

BLOOD CANCER JOURNAL, 2020, 10 (11)

← 1 2 →